Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2014

01.09.2014 | Original Research

Role of Pelvic Exenteration in the Management of Locally Advanced Primary and Recurrent Rectal Cancer

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Aim

A review of a single-centre experience of pelvic exenteration as a treatment modality for patients with locally advanced primary and recurrent rectal cancer. The perioperative outcomes, morbidity and long term oncological outcomes are reviewed.

Materials & Methods

Patients undergoing pelvic exenterations for recurrent and locally advanced rectal cancer between 1 January 2006 and 1 August 2012 were identified from a prospective database. All patients underwent pre-operative staging investigations with computed tomography (CT) scan of chest, abdomen and pelvis and pelvic magnetic resonance imaging (MRI). Patients with locally advanced primary rectal cancer were counselled for pre-operative chemoradiation. Structures such as the urinary bladder and female reproductive organs were resected en bloc where indicated with the lesion. Urological or plastic reconstructions were employed where indicated. The primary outcome measured was overall survival and secondary outcomes measured were time to local recurrence (LR) and systemic recurrence. Disease-free survival was examined by the Kaplan–Meier Method (Fig. 1).

Results

Pelvic exenterations were performed in 13 patients with a median age of 59 (range 26–81). The rate of major post-operative complications was 8 % (n = 1), where the patient had anastomotic leakage. There were no mortalities in the perioperative period. All patients were operated with curative intent and negative circumferential margins were shown in 9 out of 13 patients (70 %). The DFS was 19.4 and the OS was 22.5 months.

Conclusion

An aggressive approach with en bloc resection of organs involved provides survival benefit to patients with locally advanced primary and recurrent rectal cancer with an acceptable morbidity profile.
Literatur
1.
Zurück zum Zitat Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma: one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into colon above colostomy. Cancer. 1948;1:177–83.PubMedCrossRef Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma: one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into colon above colostomy. Cancer. 1948;1:177–83.PubMedCrossRef
2.
Zurück zum Zitat Tjandra JJ, Kilkenny JW, Buie WD, et al. Practice parameters for the Management of Rectal Cancer (Revised). Dis Colon Rectum. 2005;48:411–23.PubMedCrossRef Tjandra JJ, Kilkenny JW, Buie WD, et al. Practice parameters for the Management of Rectal Cancer (Revised). Dis Colon Rectum. 2005;48:411–23.PubMedCrossRef
3.
Zurück zum Zitat Harris DA, Davies M, Lucas MG, Drew P, Carr ND, Beynon J. Multivisceral resection for primary locally advanced rectal carcinoma. Br J Surg. 2011;98:582–8.PubMedCrossRef Harris DA, Davies M, Lucas MG, Drew P, Carr ND, Beynon J. Multivisceral resection for primary locally advanced rectal carcinoma. Br J Surg. 2011;98:582–8.PubMedCrossRef
4.
Zurück zum Zitat Park J, Guillem J. T4 And recurrent rectal cancer current clinical oncology. Rectal, Cancer. 2013;6:109–21. Park J, Guillem J. T4 And recurrent rectal cancer current clinical oncology. Rectal, Cancer. 2013;6:109–21.
5.
Zurück zum Zitat Rodriguez-Bigas MA, Petrelli NJ. Pelvic exenteration and its modifications. Am J Surg. 1996;171:293–301.CrossRef Rodriguez-Bigas MA, Petrelli NJ. Pelvic exenteration and its modifications. Am J Surg. 1996;171:293–301.CrossRef
6.
Zurück zum Zitat Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and End results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28:256–63.PubMedCentralPubMedCrossRef Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and End results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28:256–63.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Palmer G, Martling A, Lagergren P, Cedermark B, Holm T. Quality of life after potentially curative treatment for locally advanced rectal cancer. Ann Surg Oncol. 2008;15:3109–17.PubMedCrossRef Palmer G, Martling A, Lagergren P, Cedermark B, Holm T. Quality of life after potentially curative treatment for locally advanced rectal cancer. Ann Surg Oncol. 2008;15:3109–17.PubMedCrossRef
8.
Zurück zum Zitat Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007;14:1870–7.PubMedCrossRef Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007;14:1870–7.PubMedCrossRef
9.
Zurück zum Zitat Lopez MJ, Monafo WW. Role of extended resection in the initial treatment of locally advanced colorectal carcinoma. Surgery. 1993;113:365–72.PubMed Lopez MJ, Monafo WW. Role of extended resection in the initial treatment of locally advanced colorectal carcinoma. Surgery. 1993;113:365–72.PubMed
10.
Zurück zum Zitat Nielsen MB, Rasmussen PC, Lindegaard JC, Laurberg S. A 10-year experience of total pelvic exenteration for primary advanced and locally recurrent rectal cancer based on a prospective database. Colorectal Dis. 2012;14:1076–83.PubMedCrossRef Nielsen MB, Rasmussen PC, Lindegaard JC, Laurberg S. A 10-year experience of total pelvic exenteration for primary advanced and locally recurrent rectal cancer based on a prospective database. Colorectal Dis. 2012;14:1076–83.PubMedCrossRef
11.
Zurück zum Zitat Farouk R, Nelson H, Radice E, Mercill S, Gunderson L. Accuracy of computed tomography in determining resectability for locally advanced primary or recurrent colorectal cancers. Am J Surg. 1998;175:283.PubMedCrossRef Farouk R, Nelson H, Radice E, Mercill S, Gunderson L. Accuracy of computed tomography in determining resectability for locally advanced primary or recurrent colorectal cancers. Am J Surg. 1998;175:283.PubMedCrossRef
12.
Zurück zum Zitat Messiou C, Chalmers AG, Boyle K, Wilson D, Sagar P. Pre-operative MR assessment of recurrent rectal cancer. Br J Radiol. 2008;81:468–73.PubMedCrossRef Messiou C, Chalmers AG, Boyle K, Wilson D, Sagar P. Pre-operative MR assessment of recurrent rectal cancer. Br J Radiol. 2008;81:468–73.PubMedCrossRef
13.
Zurück zum Zitat Petros JG, Augustinos P, Lopez MJ. Pelvic exenteration for carcinoma of the colon and rectum. Semin Surg Oncol. 1999;17:206–12.PubMedCrossRef Petros JG, Augustinos P, Lopez MJ. Pelvic exenteration for carcinoma of the colon and rectum. Semin Surg Oncol. 1999;17:206–12.PubMedCrossRef
14.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.PubMedCrossRef Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.PubMedCrossRef
15.
Zurück zum Zitat Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;14:355–7. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;14:355–7.
16.
Zurück zum Zitat Lehnert T, Methner M, Pollok A, Schaible A, Hinz U, Herfarth C. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg. 2002;235:217–25.PubMedCentralPubMedCrossRef Lehnert T, Methner M, Pollok A, Schaible A, Hinz U, Herfarth C. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg. 2002;235:217–25.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Gohl J, Merkel S, Rodel C, Hohenberger W. Can neoadjuvant radiochemotherapy improve the results of multivisceral resections in advanced rectal carcinoma (cT4a). Colorectal Dis. 2003;5:436–41.PubMedCrossRef Gohl J, Merkel S, Rodel C, Hohenberger W. Can neoadjuvant radiochemotherapy improve the results of multivisceral resections in advanced rectal carcinoma (cT4a). Colorectal Dis. 2003;5:436–41.PubMedCrossRef
18.
Zurück zum Zitat Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CH. Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst. 2006;98:1474–81.PubMedCrossRef Govindarajan A, Coburn NG, Kiss A, Rabeneck L, Smith AJ, Law CH. Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst. 2006;98:1474–81.PubMedCrossRef
19.
20.
Zurück zum Zitat Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg. 2000;190:78–83.PubMedCrossRef Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg. 2000;190:78–83.PubMedCrossRef
22.
Zurück zum Zitat Bricker EM, Kraybill WG, Lopez MJ, Johnston WD. The current role of ultraradical surgery in the treatment of pelvic cancer. Curr Probl Surg. 1986;23:869–953.PubMedCrossRef Bricker EM, Kraybill WG, Lopez MJ, Johnston WD. The current role of ultraradical surgery in the treatment of pelvic cancer. Curr Probl Surg. 1986;23:869–953.PubMedCrossRef
23.
Zurück zum Zitat Chessin DB, Hartley J, Cohen AM, et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol. 2005;12:104–10.PubMedCrossRef Chessin DB, Hartley J, Cohen AM, et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol. 2005;12:104–10.PubMedCrossRef
24.
Zurück zum Zitat Sagar PM. Extended surgery for local recurrence and advanced rectal cancer. Colorectal Dis. 2006;8:43–6.PubMedCrossRef Sagar PM. Extended surgery for local recurrence and advanced rectal cancer. Colorectal Dis. 2006;8:43–6.PubMedCrossRef
25.
Zurück zum Zitat Pearlman NW, Donohue RE, Stiegmann GV, et al. Pelvic and sacropelvic exenteration for locally advanced or recurrent anorectal cancer. Arch Surg. 1987;122:537–41.PubMedCrossRef Pearlman NW, Donohue RE, Stiegmann GV, et al. Pelvic and sacropelvic exenteration for locally advanced or recurrent anorectal cancer. Arch Surg. 1987;122:537–41.PubMedCrossRef
Metadaten
Titel
Role of Pelvic Exenteration in the Management of Locally Advanced Primary and Recurrent Rectal Cancer
Publikationsdatum
01.09.2014
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2014
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-014-9586-y

Weitere Artikel der Ausgabe 3/2014

Journal of Gastrointestinal Cancer 3/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.